Comparative Pharmacology
Head-to-head clinical analysis: LOCORTEN versus STOBOCLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOCORTEN versus STOBOCLO.
LOCORTEN vs STOBOCLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Binds to glucocorticoid receptors, modulating gene expression to inhibit prostaglandin and leukotriene synthesis, reduce cytokine release, and suppress immune cell activation.
STOBOCLO (bupivacaine and meloxicam) is a dual-acting local anesthetic and NSAID combination. Bupivacaine blocks sodium channels in nerve fibers, preventing nerve impulse conduction and producing local anesthesia. Meloxicam inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and providing anti-inflammatory and analgesic effects.
For mild to moderate dermatoses: Apply a thin film to affected area twice daily. For severe dermatoses: Apply a thin film to affected area three to four times daily. Topical use only. Not for ophthalmic use.
Adults: 5 mg orally once daily, with or without food. Maximum dose: 10 mg once daily.
None Documented
None Documented
100 hours (terminal). Clinical context: prolonged in hepatic impairment; single daily dosing sufficient for psoriasis.
Terminal elimination half-life is 12-18 hours in adults with normal renal function, requiring dose adjustment in renal impairment.
Renal: ~75% (inactive metabolites); biliary/fecal: ~25%. <1% unchanged.
Renal excretion of unchanged drug accounts for 60-70% of elimination; fecal/biliary excretion accounts for 20-30%; the remainder is metabolized hepatically.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid